Trade

with

Raptor Pharmaceutical Corp
(NASDAQ: RPTP)
AdChoices
10.98
+0.09
+0.83%
After Hours :
10.98
0.00
0.00%

Open

10.73

Previous Close

10.89

Volume (Avg)

893.88k (646.90k)

Day's Range

10.68-11.00

52Wk Range

7.12-17.72

Market Cap.

688.92M

Dividend Rate ( Yield )

-

Beta

-0.35

Shares Outstanding

62.74M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Underperform
    • Revenue

    • 16.87M

    • Net Income

    • -69.42M

    • Market Cap.

    • 688.92M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -125.73

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -0.35

    • Forward P/E

    • -32.26

    • Price/Sales

    • 14.93

    • Price/Book Value

    • 38.91

    • Price/Cash flow

    • -17.79

      • EBITDA

      • -62.15M

      • Return on Capital %

      • -62.01

      • Return on Equity %

      • -291.05

      • Return on Assets %

      • -62.01

      • Book Value/Share

      • 0.28

      • Shares Outstanding

      • 62.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Underperform
        • 1 Year Price Target

        • 7.00

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -0.30

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • 22.68

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 92.19

            • 69.92

            • Pre-Tax Margin

            • -125.70

            • 21.84

            • Net Profit Margin

            • -125.73

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 2.68

              • 0.32

              • Current Ratio

              • 3.03

              • 1.92

              • Quick Ratio

              • 2.55

              • 1.31

              • Interest Coverage

              • -3.95

              • 17.64

              • Leverage Ratio

              • 5.09

              • 2.03

              • Book Value/Share

              • 0.28

              • 14.62

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -11.45

                • 22.99

                • P/E Ratio 5-Year High

                • -19.16

                • 193.96

                • P/E Ratio 5-Year Low

                • -1.25

                • 87.26

                • Price/Sales Ratio

                • 14.39

                • 3.84

                • Price/Book Value

                • 37.45

                • 3.83

                • Price/Cash Flow Ratio

                • -17.79

                • 14.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -291.05

                    (-)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • -62.01

                    (-)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • -65.25

                    (-)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • -

                  • 90.07k

                  • Inventory Turnover

                  • 0.82

                  • 2.46

                  • Asset Turnover

                  • 0.49

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -51.91M
                  Operating Margin
                  -307.65
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -17.79
                  Ownership

                  Institutional Ownership

                  68.16%

                  Top 10 Institutions

                  56.48%

                  Mutual Fund Ownership

                  19.04%

                  Float

                  98.62%

                  5% / Insider Ownership

                  7.85%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,853,057

                  • 0.00

                  • 4.55

                  • SPDR® S&P Biotech ETF

                  •  

                    1,405,615

                  • -1.92

                  • 2.54

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,026,156

                  • 0.00

                  • 1.64

                  • iShares Russell 2000 (AU)

                  •  

                    931,416

                  • -1.46

                  • 1.69

                  • iShares Nasdaq Biotechnology

                  •  

                    811,734

                  • -0.47

                  • 1.47

                  • Vanguard Extended Market Index Fund

                  •  

                    614,056

                  • 0.45

                  • 0.98

                  • iShares Russell 2000 Growth

                  •  

                    444,183

                  • 0.34

                  • 0.80

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    228,373

                  • 0.00

                  • 0.36

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    210,398

                  • 0.00

                  • 0.34

                  • Rydex Series Trust Biotechnology Fund

                  •  

                    196,532

                  • 73.26

                  • 0.31

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Sequoia Asset Management S A

                  •  

                    7,713,008

                  • -9.29%

                  • 12.52

                  • Credit Suisse First Boston (CSFB)

                  •  

                    4,462,211

                  • +3.18%

                  • 7.12

                  • Goldman, Sachs & Co.

                  •  

                    3,875,182

                  • +38.36%

                  • 6.18

                  • Fidelity Management and Research Company

                  •  

                    3,081,430

                  • -7.53%

                  • 4.92

                  • Royal Bank Of Canada

                  •  

                    3,029,523

                  • +1.95%

                  • 4.83

                  • BlackRock Fund Advisors

                  •  

                    2,282,653

                  • -5.92%

                  • 3.64

                  • State Street Corp

                  •  

                    2,246,873

                  • -13.08%

                  • 3.58

                  • Vanguard Group, Inc.

                  •  

                    1,906,499

                  • +2.58%

                  • 3.04

                  • Group One Trading, LP

                  •  

                    1,059,887

                  • +8.12%

                  • 1.69

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Distressed

                  Style

                  Small Core

                  Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Thera...morepeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. The Company is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The Company's product, PROCYSBI® cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the man...moreagement of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of proven nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of innovative microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a highly-reactive molecule generated in the cell during the metabolism of cysteine. The Company’s pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company’s preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia™ its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company’s product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in significant additional expense.lessless

                  Key People

                  Dr. Christopher M. Starr,PhD

                  CEO/Director

                  Dr. Llew Keltner,M.D.,PhD

                  Chairman of the Board/Director

                  Ms. Georgia L. Erbez

                  CFO/Chief Accounting Officer/Secretary/Treasurer

                  Erich Sager

                  Director

                  Dr. Richard L. Franklin,M.D.,PhD

                  Director

                  • Raptor Pharmaceutical Corp

                  • 5 Hamilton Landing

                  • Novato, CA 94949

                  • USA.Map

                  • Phone: +1 415 408-6200

                  • Fax: +1 415 382-8002

                  • raptorpharma.com

                  Incorporated

                  1997

                  Employees

                  72

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: